Literature DB >> 26110232

The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers.

Manon Suerink1, Heleen M van der Klift2, Sanne W Ten Broeke1, Olaf M Dekkers3, Inge Bernstein4,5, Gabriel Capellá Munar6, Encarna Gomez Garcia7, Nicoline Hoogerbrugge8,9, Tom G W Letteboer10, Fred H Menko11, Annika Lindblom12,13, Arjen Mensenkamp14, Pal Moller15, Theo A van Os16, Nils Rahner17, Bert J W Redeker16, M J W Olderode-Berends, Maran Olderode18, Liesbeth Spruijt9, Yvonne J Vos18, Anja Wagner19, Hans Morreau20, Frederik J Hes1, Hans F A Vasen21, Carli M Tops1, Juul T Wijnen3, Maartje Nielsen1.   

Abstract

PURPOSE: Lynch syndrome (LS), a heritable disorder with an increased risk of primarily colorectal cancer (CRC) and endometrial cancer (EC), can be caused by mutations in the PMS2 gene. We wished to establish whether genotype and/or parent-of-origin effects (POE) explain (part of) the reported variability in severity of the phenotype.
METHODS: European PMS2 mutation carriers (n = 381) were grouped and compared based on RNA expression and whether the mutation was inherited paternally or maternally.
RESULTS: Mutation carriers with loss of RNA expression (group 1) had a significantly lower age at CRC diagnosis (51.1 years vs. 60.0 years, P = 0.035) and a lower age at EC diagnosis (55.8 years vs. 61.0 years, P = 0.2, nonsignificant) compared with group 2 (retention of RNA expression). Furthermore, group 1 showed slightly higher, but nonsignificant, hazard ratios (HRs) for both CRC (HR: 1.31, P = 0.38) and EC (HR: 1.22, P = 0.72). No evidence for a significant parent-of-origin effect was found for either CRC or EC.
CONCLUSIONS: PMS2 mutation carriers with retention of RNA expression developed CRC 9 years later than those with loss of RNA expression. If confirmed, this finding would justify a delay in surveillance for these cases. Cancer risk was not influenced by a parent-of-origin effect.Genet Med 18 4, 405-409.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26110232     DOI: 10.1038/gim.2015.83

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  19 in total

1.  Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.

Authors:  Ester Borràs; Marta Pineda; Juan Cadiñanos; Jesús Del Valle; Angela Brieger; Inga Hinrichsen; Ruben Cabanillas; Matilde Navarro; Joan Brunet; Xavier Sanjuan; Eva Musulen; Helen van der Klift; Conxi Lázaro; Guido Plotz; Ignacio Blanco; Gabriel Capellá
Journal:  J Med Genet       Date:  2013-05-24       Impact factor: 6.318

2.  Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients.

Authors:  Heleen M van der Klift; Carli M J Tops; Elsa C Bik; Merel W Boogaard; Anne-Marijke Borgstein; Kerstin B M Hansson; Margreet G E M Ausems; Encarna Gomez Garcia; Andrew Green; Frederik J Hes; Louise Izatt; Liselotte P van Hest; Angel M Alonso; Annette H J T Vriends; Anja Wagner; Wendy A G van Zelst-Stams; Hans F A Vasen; Hans Morreau; Peter Devilee; Juul T Wijnen
Journal:  Hum Mutat       Date:  2010-05       Impact factor: 4.878

3.  The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair.

Authors:  Suzanne M Deschênes; Guy Tomer; Megan Nguyen; Naz Erdeniz; Nicole C Juba; Natalia Sepúlveda; Jenna E Pisani; R Michael Liskay
Journal:  Cancer Lett       Date:  2006-10-09       Impact factor: 8.679

4.  Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome.

Authors:  Lucía Pérez-Cabornero; Mar Infante; Eladio Velasco; Enrique Lastra; Cristina Miner; Mercedes Durán
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

Review 5.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

6.  Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations.

Authors:  P Peltomäki; X Gao; J P Mecklin
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

7.  Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred with a common MSH2 mutation.

Authors:  Jane Green; Mary O'Driscoll; Adam Barnes; Eamonn R Maher; Peter Bridge; Keith Shields; Patrick S Parfrey
Journal:  Dis Colon Rectum       Date:  2002-09       Impact factor: 4.585

8.  A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts.

Authors:  Wenche Sjursen; Inga Bjørnevoll; Lars F Engebretsen; Kristine Fjelland; Tore Halvorsen; Helge E Myrvold
Journal:  Fam Cancer       Date:  2008-11-28       Impact factor: 2.375

9.  The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.

Authors:  Leigha Senter; Mark Clendenning; Kaisa Sotamaa; Heather Hampel; Jane Green; John D Potter; Annika Lindblom; Kristina Lagerstedt; Stephen N Thibodeau; Noralane M Lindor; Joanne Young; Ingrid Winship; James G Dowty; Darren M White; John L Hopper; Laura Baglietto; Mark A Jenkins; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2008-05-02       Impact factor: 22.682

10.  Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).

Authors:  Johanne Geary; Peter Sasieni; Richard Houlston; Louise Izatt; Ros Eeles; Stewart J Payne; Samantha Fisher; Shirley V Hodgson
Journal:  Fam Cancer       Date:  2007-10-16       Impact factor: 2.375

View more
  8 in total

1.  Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.

Authors:  Fay Kastrinos; Hajime Uno; Chinedu Ukaegbu; Carmelita Alvero; Ashley McFarland; Matthew B Yurgelun; Matthew H Kulke; Deborah Schrag; Jeffrey A Meyerhardt; Charles S Fuchs; Robert J Mayer; Kimmie Ng; Ewout W Steyerberg; Sapna Syngal
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

2.  A Lynch syndrome-associated mutation at a Bergerat ATP-binding fold destabilizes the structure of the DNA mismatch repair endonuclease MutL.

Authors:  Keisuke Izuhara; Kenji Fukui; Takeshi Murakawa; Seiki Baba; Takashi Kumasaka; Kazuhisa Uchiyama; Takato Yano
Journal:  J Biol Chem       Date:  2020-06-22       Impact factor: 5.157

Review 3.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

4.  Do the risks of Lynch syndrome-related cancers depend on the parent of origin of the mutation?

Authors:  Shimelis Dejene Gemechu; Christine M van Vliet; Aung Ko Win; Jane C Figueiredo; Loic Le Marchand; Steven Gallinger; Polly A Newcomb; John L Hopper; Noralane M Lindor; Mark A Jenkins; James G Dowty
Journal:  Fam Cancer       Date:  2020-02-27       Impact factor: 2.446

5.  Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients.

Authors:  Jiang-Yi Wang; Shuang-He Peng; Xiang-Hui Ning; Teng Li; Sheng-Jie Liu; Jia-Yuan Liu; Bao-An Hong; Nie-Nie Qi; Xiang Peng; Bo-Wen Zhou; Jiu-Feng Zhang; Lin Cai; Kan Gong
Journal:  Cancer Med       Date:  2017-08-04       Impact factor: 4.452

6.  SNP association study in PMS2-associated Lynch syndrome.

Authors:  Sanne W Ten Broeke; Fadwa A Elsayed; Lisa Pagan; Maran J W Olderode-Berends; Encarna Gomez Garcia; Hans J P Gille; Liselot P van Hest; Tom G W Letteboer; Lizet E van der Kolk; Arjen R Mensenkamp; Theo A van Os; Liesbeth Spruijt; Bert J W Redeker; Manon Suerink; Yvonne J Vos; Anja Wagner; Juul T Wijnen; E W Steyerberg; Carli M J Tops; Tom van Wezel; Maartje Nielsen
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

7.  No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study.

Authors:  Mev Dominguez-Valentin; John-Paul Plazzer; Julian R Sampson; Christoph Engel; Stefan Aretz; Mark A Jenkins; Lone Sunde; Inge Bernstein; Gabriel Capella; Francesc Balaguer; Finlay Macrae; Ingrid M Winship; Huw Thomas; Dafydd Gareth Evans; John Burn; Marc Greenblatt; Wouter H de Vos Tot Nederveen Cappel; Rolf H Sijmons; Maartje Nielsen; Lucio Bertario; Bernardo Bonanni; Maria Grazia Tibiletti; Giulia Martina Cavestro; Annika Lindblom; Adriana Della Valle; Francisco Lopez-Kostner; Karin Alvarez; Nathan Gluck; Lior Katz; Karl Heinimann; Carlos A Vaccaro; Sigve Nakken; Eivind Hovig; Kate Green; Fiona Lalloo; James Hill; Hans F A Vasen; Claudia Perne; Reinhard Büttner; Heike Görgens; Elke Holinski-Feder; Monika Morak; Stefanie Holzapfel; Robert Hüneburg; Magnus von Knebel Doeberitz; Markus Loeffler; Nils Rahner; Jürgen Weitz; Verena Steinke-Lange; Wolff Schmiegel; Deepak Vangala; Emma J Crosbie; Marta Pineda; Matilde Navarro; Joan Brunet; Leticia Moreira; Ariadna Sánchez; Miquel Serra-Burriel; Miriam Mints; Revital Kariv; Guy Rosner; Tamara Alejandra Piñero; Walter Hernán Pavicic; Pablo Kalfayan; Sanne W Ten Broeke; Jukka-Pekka Mecklin; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; Anna Lepistö; Päivi Peltomäki; John L Hopper; Aung Ko Win; Daniel D Buchanan; Noralane M Lindor; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Jane C Figueiredo; Stephen N Thibodeau; Christina Therkildsen; Thomas V O Hansen; Lars Lindberg; Einar Andreas Rødland; Florencia Neffa; Patricia Esperon; Douglas Tjandra; Gabriela Möslein; Toni T Seppälä; Pål Møller
Journal:  J Clin Med       Date:  2021-06-28       Impact factor: 4.241

8.  Cancer Risks for PMS2-Associated Lynch Syndrome.

Authors:  Sanne W Ten Broeke; Heleen M van der Klift; Carli M J Tops; Stefan Aretz; Inge Bernstein; Daniel D Buchanan; Albert de la Chapelle; Gabriel Capella; Mark Clendenning; Christoph Engel; Steven Gallinger; Encarna Gomez Garcia; Jane C Figueiredo; Robert Haile; Heather L Hampel; John L Hopper; Nicoline Hoogerbrugge; Magnus von Knebel Doeberitz; Loic Le Marchand; Tom G W Letteboer; Mark A Jenkins; Annika Lindblom; Noralane M Lindor; Arjen R Mensenkamp; Pål Møller; Polly A Newcomb; Theo A M van Os; Rachel Pearlman; Marta Pineda; Nils Rahner; Egbert J W Redeker; Maran J W Olderode-Berends; Christophe Rosty; Hans K Schackert; Rodney Scott; Leigha Senter; Liesbeth Spruijt; Verena Steinke-Lange; Manon Suerink; Stephen Thibodeau; Yvonne J Vos; Anja Wagner; Ingrid Winship; Frederik J Hes; Hans F A Vasen; Juul T Wijnen; Maartje Nielsen; Aung Ko Win
Journal:  J Clin Oncol       Date:  2018-08-30       Impact factor: 50.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.